Introduction {#Sec1}
============

Prevention of osteoporotic fractures depends on the identification of individuals at risk for fractures, followed by interventions to reduce this risk, such as modification of lifestyle factors and use of bone-sparing medications \[[@CR1], [@CR2]\]. The presence of a low trauma fracture is a significant risk factor for predicting future fracture; about 50% of those that survive experience a subsequent fracture in 10 years \[[@CR3]\]. Clinical practice guidelines state that a low trauma fracture should signal the opportunity to initiate osteoporosis treatment for prevention of subsequent fractures \[[@CR1], [@CR2]\].

Two systematic reviews concluded that despite the availability of effective treatment options, the majority of patients who experience a low trauma fracture are under-investigated and under-treated for osteoporosis, within Canada and internationally \[[@CR4], [@CR5]\]. This highlights an important care gap \[[@CR6]\]. In Europe and North America, the care gap has resulted in action plans to improve bone health \[[@CR7]--[@CR10]\]. One such plan, currently being implemented, is the Ontario Osteoporosis Strategy, a population-based chronic disease management program \[[@CR10]\]. The overall goal is to reduce morbidity, mortality and costs from osteoporosis and related fractures by raising public awareness, changing knowledge, attitudes and behaviours of both the public and health professionals and improving prevention and treatment programs.

Secondary fracture prevention is a major focus with a province-wide Fracture Clinic Screening Program implemented in 36 medium- and high-volume fracture clinics. Based on the Osteoporosis Exemplary Care Program developed by Bogoch et al. \[[@CR11]\], Screening Coordinators conduct an osteoporosis assessment, provide education, refer low trauma fracture patients to their primary care physician for follow-up and send a letter recommending that the patient be assessed for osteoporosis with bone mineral density (BMD) testing. Unfortunately, by restricting the Osteoporosis Strategy coordinators to medium and large volume hospitals with fracture clinics, the program misses about one third of fracture patients in Ontario who are treated in small community hospitals as funding an osteoporosis coordinator is not justifiable in each small community hospital. Yet, similar to others \[[@CR12], [@CR13]\], we have previously shown that an educational intervention alone was not sufficient to improve practice \[[@CR14]\], suggesting the need for a more targeted intervention in smaller communities. There have been a number of recent randomized controlled trials of post-fracture care interventions that have reported positive effects \[[@CR15]--[@CR23]\] with a pooled absolute improvement in osteoporosis treatment rates of 20% over and above usual care \[[@CR24]\]. However, in all of these trials the majority of patients were recruited from academic centres or health maintenance organizations with high fracture volumes and access to osteoporosis specialists.

The current cluster randomized trial was conducted to determine if an intervention based on the osteoporosis coordinator role in the focused environment of a high-volume urban fracture clinic can be effective when adapted to smaller community hospitals. We hypothesized that a centralized coordinator who identifies and follows up with fracture patients and their primary care physicians by telephone and mail will increase the proportion of patients who receive appropriate investigation and treatment for osteoporosis compared with simple fall prevention advice among patients.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

We conducted a cluster randomized trial in which the hospital emergency department was the unit (cluster) of allocation and men and women with a low trauma fracture were the unit of analysis. Since the purpose of the trial was to change practice behaviour and patients in these communities were likely to have the same primary care physician, a cluster design was chosen to minimize contamination.

Setting and participants {#Sec4}
------------------------

### Hospital eligibility criteria and recruitment {#Sec5}

Hospitals without a dedicated osteoporosis screening coordinator that treated more than 60 fracture patients per year in their Emergency Department (ED) and who were members of the Ontario Telemedicine Network were potentially eligible (*n* = 54). Information letters were sent to the hospitals explaining the study and site visits were conducted by the centralized coordinator. Ethics approval was obtained from the Research Ethics Board of the Toronto Rehabilitation Institute and each of the participating sites.

### Patient eligibility criteria and recruitment {#Sec6}

Emergency Department records provided through the National Ambulatory Care Reporting System database at each hospital site were used to identify all new cases of fracture. Records of patients 40 years and older presenting with a fracture of the hip, forearm, wrist, rib(s), sternum, thoracic and lumbar spine, shoulder and upper arm, pelvis, lower leg and ankle were identified. Patients with 'cause of injury' codes indicating the fracture was not likely due to a fall from a standing height (e.g. transportation accidents or other major trauma), who were residing in a nursing home, or with fractures that occurred more than 3 months between the time of their initial ED visit and preparation of the list for the centralized coordinator were excluded. On a monthly basis, a list of fracture patients was provided to the centralized coordinator. Participants were recruited by telephone between January and July 2008 and further screened with the following exclusion criteria: unable to contact, died, in long-term care, cognitive or hearing impairment, lived outside of region and previously screened by an Osteoporosis Strategy coordinator at another hospital.

### Intervention {#Sec7}

The multi-faceted intervention was comprised of having the centralized coordinator, a physical therapist, follow-up with fracture patients and their physicians to provide evidenced-based recommendations about fracture risk and osteoporosis treatment and assist with arranging telehealth consultations to the Multidisciplinary Osteoporosis Program (MOP) \[[@CR25]\] at a teaching hospital for complex patients if requested.

### Patient component {#Sec8}

In the intervention arm, the centralized coordinator phoned fracture patients and counselled them about their risk of osteoporosis, the need to follow-up with their primary care physician to discuss osteoporosis and the need for a BMD test and provided information about existing resources for osteoporosis management. A standard baseline questionnaire was completed, and consent was obtained for the research assistant to contact them and collect follow-up data. Each patient was sent a personalized letter reiterating the conversation. Three months later, they received a reminder phone call from the coordinator and were encouraged to follow-up with their primary care physician if they had not already done so. At 6 months, patients completed a follow-up questionnaire administered by the research assistant who was blinded to treatment allocation.

### Physician component {#Sec9}

The centralized coordinator sent the patient's primary care physician a letter informing them that their patient had experienced a fracture. The letter was tailored for each patient and highlighted: (1) the patient's high risk for osteoporosis and need for a BMD test if one has not been done in the past 6 months, (2) high 1-year fracture risk in the presence of fracture and BMD T-score is ≤1.5 if the patient goes untreated \[[@CR26]\], (3) efficacy of first-line treatment with bisphosphonates on fracture risk, and (4) availability of osteoporosis specialist consultation through the MOP if desired. Physicians were asked to place the letter in the patient's office chart as a point-of-care reminder for the next visit. Primary care physicians also received pocket cards containing evidence-based recommendations about appropriate BMD testing and treatment based on the most recent Canadian guidelines available at the time of the trial \[[@CR1], [@CR27]\].

### Attention controls {#Sec10}

Similar to the intervention hospitals, within 3 months of the ED visit for fracture, patients from the control hospitals received educational material and telephone counseling regarding fall prevention and home safety from the centralized coordinator. Patients were encouraged to visit their primary care physician for a more detailed advice and medication review. They did not receive counseling or educational materials about osteoporosis. The coordinator administered the baseline questionnaire and obtained consent for the research assistant to collect follow-up data at 6 months. The control group did not receive the 3-month reminder phone call.

Outcomes and measurements {#Sec11}
-------------------------

The primary outcome was the proportion of patients self-reporting 'appropriate management', defined as receiving, within 6 months of fracture, either an osteoporosis medication (bisphosphonate, raloxifene or teriparatide) or normal BMD and prevention advice. Previous research has shown excellent agreement between self-report and dispensing records for osteoporosis medications \[[@CR28], [@CR29]\] and self-report for having had a BMD test \[[@CR30]\]. This composite outcome was chosen because unlike the other post-fracture care trials that excluded patients already taking osteoporosis medications \[[@CR15]--[@CR23]\], this trial included patients who were already on treatment for osteoporosis when they experienced a low trauma fracture. The Canadian guidelines recommended that these patients should have their BMD reassessed and medications reviewed \[[@CR1], [@CR27]\]. Secondary outcomes were: the proportion of patients with a physician visit to discuss osteoporosis after fracture, and the proportion for which BMD was scheduled or performed.

Sample size {#Sec12}
-----------

The sample size was based on a binary outcome (appropriate management---yes/no). In a survey of osteoporosis researchers and clinicians from Canada and the USA, the median response reported for a 'minimal clinically important difference' for a post-fracture care intervention was 20% over and above 'usual care' \[[@CR31]\]. From our demonstration project in five small communities in Ontario \[[@CR14]\], we found that 31% of patients had a BMD test after fracture. We anticipated a cluster size of ten patients per hospital and an intra-cluster correlation coefficient of 0.01 \[[@CR32]\]. Therefore, we needed to identify about 20 fracture patients in each of 30 hospitals to detect an effect size of 20% (intervention = 50% and controls = 30%) with 90% power. Therefore, the final sample was at least 300 patients (ten patients per cluster with 15 intervention and 15 control clusters). The level of statistical significance was set at *p* \< 0.05.

Randomization {#Sec13}
-------------

Hospitals that agreed to participate were assigned by simple random allocation to invention or attention control. Randomization was performed with a computer program by the statistician who was blind to the hospitals' identity. The investigators and the research assistant collecting the outcome information were blinded to treatment allocation

Statistical analyses {#Sec14}
--------------------

To assess the quality of randomization, demographic and clinical characteristics in the intervention and control groups were calculated using descriptive statistics. To assess for differences between outcomes in the intervention and control groups, multi-level hierarchical modelling using the General Estimating Equation (GEE) approach was used to account for clustering to estimate the treatment effect as an odds ratio and test for significance \[[@CR33], [@CR34]\]. First-order interaction terms (specifically: sex by intervention status) were evaluated. The 95% confidence intervals and *p* values were calculated using the sandwich estimator of variance. The analysis was carried out using *R: A Language and Environment for Statistical Computing* version 2.10.1 \[[@CR35], [@CR36]\]. The GEE models were fit using the *R* package *geepack* version 1.0-17.

Results {#Sec15}
=======

Study flow {#Sec16}
----------

Of the 54 eligible hospitals, 36 agreed to participate and were randomly assigned to intervention or control group (18 in each group). We obtained 801 records for fracture patients within 3 months of their admission to the ED; 139 were received 3 months after fracture. Of these, 443 were excluded: 298 were unable to reach, 51 had died or were in long-term care, 43 lived outside of the hospital catchment area, 21 refused, 18 had previously been screened by a fracture clinic coordinator and 12 had significant cognitive or hearing impairment, resulting in 358 enrolled subjects (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flow of patients through the trial

Cluster size was comparable between the groups with ten (range, 3--16) in the intervention and ten (range, 4--18) in the control hospitals. Of those randomized, 52 from the intervention hospitals and 39 from the control hospitals were lost to follow-up leaving a total of 267 subjects with complete data for analysis. The primary analysis is a 'complete case' and includes only those whose outcome is known \[[@CR37]\]. A secondary analysis was the strict intention to treat analysis in which all randomized subjects were included.

Baseline characteristics {#Sec17}
------------------------

The mean age of the study participants was 66.0 years in the intervention and 65.4 in the control group; about two thirds were female and married. Twenty-seven percent had a history of a previous fracture since the age of 40 years, 20% were current smokers and 23% had fallen in the previous 12 months. Thirty-one percent had a BMD test in the previous 12 months, 25% self-reported a diagnosis of osteoporosis and 19% were currently taking osteoporosis medications. The most common fracture type was wrist (34%), followed by ankle (16%), rib (12%), shoulder (12%) and hip (8%). There was no significant difference in demographic and clinical characteristics among patients in the intervention and control groups (Table [1](#Tab1){ref-type="table"}). Table 1Baseline demographic and clinical characteristics, *N* = 267Characteristic*N*Intervention (*n* = 130; mean (SD) or (%))Control (*n* = 137; mean (SD) or (%))Demographic characteristicsAge in years26766.0 (11.0)65.4 (11.6)Female26796 (74%)93 (68%)College/university education26550 (39%)58 (42%)Married26684 (65%)93 (68%)Living alone25928 (23%)35 (26%)Employed full-time26632 (24%)44 (32%)Clinical characteristicsPrior fracture since age 4026636 (28%)36 (26%)Maternal history of hip fracture26711 (8%)8 (6%)Current smoker26625 (19%)27 (20%)Current weight (lbs---mean (SD))265166.2 (33.2)162.5 (34.7)History of falls in past 12 months26629 (22%)33 (24%)Have trouble getting out of chair or unsteady when walking26723 (18%)22 (16%)Oral steroid use for \>3 months26511 (8%)4 (3%)Rheumatoid arthritis2654 (3%)2 (1%)More than 2 alcoholic drinks daily2635 (4%)0 (0%)Osteoporosis diagnosis26531 (24%)36 (27%)Currently taking osteoporosis medications26725 (19%)26 (19%)Bone mineral density test in past 12 months26538 (29%)44 (32%)Fracture type267Wrist48 (37%)44 (32%)Ankle16 (12%)26 (19%)Rib16 (12%)15 (11%)Shoulder15 (11%)15 (11%)Hip12 (9%)9 (6%)Tibia/fibula7 (5%)13 (9%)Humerus5 (4%)3 (2%)Spine2 (1%)2 (1%)Pelvis3 (2%)1 (1%)

Outcomes {#Sec18}
--------

The intervention increased the proportion of patients who received appropriate management, defined as taking an osteoporosis medication or normal BMD and prevention advice within 6 months of fracture: 45% (59/130) in the intervention group compared with 26% (35/137) in the control group, giving an absolute difference of 20%; cluster-adjusted OR, 2.3; 95% CI, 1.3--4.1; *p* = 0.003 (Table [2](#Tab2){ref-type="table"}). Of the 45% in the intervention group appropriately managed, 23% had normal BMD and 22% were on treatment and of the 26% in the control group, 9% had normal BMD and 17% were on treatment. The proportion who had a BMD test scheduled or performed was much higher (57% of intervention patients compared with 21% of controls; cluster-adjusted OR, 4.8; 95% CI, 3.0--7.0; *p* \< 0.0001). The intervention resulted in the majority of patients having a discussion about osteoporosis with their physician: 82.2% intervention compared with 55.4% control patients; cluster-adjusted OR, 3.8; 95% CI, 2.3--6.3; *p* \< 0.0001. For the strict intention to treat analysis in which all randomized subjects are included, the corresponding proportions for appropriate management are 32% (59/182) in the intervention and 20% (35/176) in the control, *p* = 0.007. Table 2Primary and secondary outcomes 6 months post-fractureOutcomeIntervention (*N* = 130 (%))Control (*N* = 137 (%))Intra-cluster correlation coefficientAdjusted odds^a^ ratio (95% CI)*P* valuePhysician discussed osteoporosis82.255.4−0.0123.8 (2.3--6.3)\<0.001BMD test57.421.3−0.0264.8 (3.0--7.9)\<0.001Appropriate management45.425.90.0092.3 (1.3--4.1)0.003^a^Adjusted for age and sex

Male and female differences {#Sec19}
---------------------------

For each of the three outcomes in the hierarchical modelling a test for an intervention by sex interaction was not statistically significant. Of the 267 study participants with outcome data, 29% were male. When analyses were restricted to the intervention group, only 29% of males compared with 51% of females were appropriately managed (Table [3](#Tab3){ref-type="table"}) while the proportions that had a BMD test scheduled or performed (50% males compared with 59% females) and that saw their primary care physician (76% males and 84% females) were similar. Table 3Primary and secondary outcomes among males and females by allocation to intervention or control groupOutcomeInterventionControlMales (*n* = 34; %)Females (*n* = 96; %)Males (*n* = 44; %)Females (*n* = 93; %)Physician discussed osteoporosis76.484.259.152.7BMD test50.059.413.624.7Appropriate management29.451.0^a^9.134.4^aa^Subgroup comparison of males and females within each of intervention and control group, *p* \< 0.05

Discussion {#Sec20}
==========

This cluster randomized trial in 36 small community hospitals with 267 study participants who suffered a low trauma fracture found that the multi-faceted intervention resulted in a significant increase in the proportion of patients appropriately managed within 6 months of fracture among the intervention compared to patients in the control group, about a 20% absolute difference. The intervention also resulted in more patients having a BMD scheduled or performed and most having a discussion about osteoporosis with their primary care physician compared to patients in the control group.

To our knowledge, this is the first and only randomized trial that has been restricted to patients from small or rural communities. To date, there have been nine published post-fracture care randomized controlled trials \[[@CR24]\] that have evaluated various interventions to improve management of osteoporosis in this high-risk population. Two of these were cluster randomized trials \[[@CR19], [@CR20]\], one in a health maintenance organization with a large number of primary care practices \[[@CR16]\], three in one or two hospitals \[[@CR17], [@CR21], [@CR23]\] and four in-patient interventions for those with hip fracture \[[@CR15], [@CR17], [@CR18], [@CR22]\]. The pooled absolute improvements across these nine trials in BMD testing was 36% and for osteoporosis treatment 20% (95% CI, 10--30) which is virtually identical to what we observed in terms of our pre-defined outcome of appropriate osteoporosis management.

The interventions vary in many of the nine prior randomized trials, ranging from point-of-care reminders to physicians to patient-specific education. This is reflected in the heterogeneity seen when trying to pool results (e.g. an I2 of 88% for improvements in osteoporosis treatment) \[[@CR24]\]. In the study by Feldstein et al. \[[@CR16]\], the intervention was an electronic medical record reminder which resulted in 52% of intervention patients getting a BMD test or osteoporosis medication at 6 months compared with 6% of the usual care. Whereas, in the study by Majumdar et al. \[[@CR21]\], the intervention was multi-faceted with telephone-based nurse led education, a patient-specific reminder sent to the physician and guidelines endorsed by local opinion leaders. These findings with 22% of intervention and 7% of control patients on treatment with a bisphosphonate 6 months after a wrist fracture are similar to those reported by Cranney et al. \[[@CR20]\] who only used mailed reminders to patients and primary care physicians and a patient education package. Rozenthal et al. \[[@CR23]\] randomized 50 distal radius fracture patients to either the orthopaedic surgeon ordering a BMD test and forwarding the results to the primary care physician or just sending a letter to the primary care physician outlining guidelines for osteoporosis screening. Initiation of osteoporosis therapy was much higher (74%) than in other studies but this trial did not only consider treatment with bisphosphonates but also counted initiation with calcium and vitamin D as a treatment outcome.

We believe the key factor to the success of our intervention was that the coordinator empowered the patient to ask for a BMD test and made the patient the 'reminder' for the physician. This particular combination of a multi-faceted intervention, where you have a triad of a coordinator, patient and primary care physician, should be evaluated as a model for improving guideline adherence for other chronic diseases, particularly among physicians in smaller communities with limited access to specialist care.

One of the advantages of the current trial is the ability to examine sex differences in post-fracture osteoporosis management. Previous research has shown that the care gap is significant in both men and women but more so in men \[[@CR38], [@CR39]\]. Our study has shown that care improved for both; however, there are still substantially greater care gaps in men versus women, as others have shown despite interventions; possible reasons are men and their physicians view osteoporosis as a disease of elderly women \[[@CR40], [@CR41]\] and more importantly, guidelines are unclear about treatment options. In the new 2010 Canadian guidelines, there is grade A evidence for investigating men with a fracture but grade D evidence for prescribing bisphosphonate therapy in men \[[@CR42]\].

This study had a number of strengths. This was a randomized trial with a cluster design which minimized contamination because hospital sites rather than individual patients were randomized. The cluster design also increases the generalizability of the findings since the study was carried out in a large number of hospitals. This is the only randomized trial published to date of a post-fracture care intervention in rural communities without access to osteoporosis specialists and in many cases orthopaedic surgeons. One of the limitations of this study is the potential for selection bias as were unable to reach a large proportion of eligible patients. These patients were called a maximum of seven times at different times of the day and messages were left where possible. These could be individuals who were not interested in additional follow-up for their fracture, thus, limiting the generalizability of the findings. In the future, one way to improve this may be to send patients a letter informing them about the program before the coordinator calls. In addition, the loss to follow-up was greater in among intervention patients. As a result the 'complete case' analysis would potentially overestimate the impact of the intervention since those lost to follow-up in the intervention probably did not want to be contacted again if they did not comply with the coordinator's suggestions made at baseline. Another potential limitation is the lack of quality control procedures to assess treatment fidelity. The coordinator was not taped or observed when delivering the intervention. It was assumed that treatment fidelity was high given that the centralized coordinator was a physical therapist with expertise in osteoporosis management.

Our findings are also limited by the fact that we relied on self-report data, which may have biased our estimate of appropriate management since we did not have access to the actual BMD reports or patient charts. A validation study of DXA results identifies that patients underestimate bone loss, and although 84% of patients with normal BMD by DXA correctly identify their bones as normal, 49% with 'osteopenia' and 15% with osteoporosis also state that their bones are normal \[[@CR30]\]. This would overestimate our findings for appropriate management. Similar to all of the other post-fracture care randomized trials, we measured 'process' outcomes, BMD testing and appropriate management, and not a clinical endpoint, such as recurrent fracture. However, receipt of a BMD test and/or use of a medication for osteoporosis is considered an important quality of care indicator, used by the majority of health plans in the USA to measure performance of the health care system \[[www.ncqa.org](http://www.ncqa.org)\].

In conclusion, we found that a multi-faceted intervention with a centralized osteoporosis coordinator is effective in improving osteoporosis care in smaller communities that do not have access to osteoporosis specialists, but there is still a care gap. There are number of ways in which this intervention could be improved. There could be better advertising of the program. For example, there could be pamphlets/posters in the waiting room and more importantly staff in the ED could mention to fracture patients the link between osteoporosis and fracture and that the hospital has a special program for fracture patients. Rates of BMD testing are higher than appropriate management suggesting that interventions in the future need to address issues with reporting and interpretation of bone density measurements and fracture risk in treatment decision making. Treatment rates might be higher if patients understood their BMD results better for example this could be achieved with a standardized report for the family physicians outlining fracture risk and treatment recommendations and a patient-specific BMD report. We also need to improve our efforts to disseminate information about the importance of osteoporosis in men to health care providers and clarify treatment recommendations. Finally, in terms of knowledge translation this intervention is best suited for a universal or managed care setting.
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